123 related articles for article (PubMed ID: 20565793)
21. [Total thyroidectomy of choice in papillary microcarcinoma].
Pisello F; Geraci G; Sciumè C; Li Volsi F; Modica G
G Chir; 2007; 28(1-2):13-9. PubMed ID: 17313727
[TBL] [Abstract][Full Text] [Related]
22. Squamous cell components in a thyroid follicular adenoma: significant evidence of follicular cell origin by histomorphological, immunohistochemical and molecular analyses.
Bai Y; Mori I; Liu Z; Li Y; Ozaki T; Taniguchi E; Asai M; Naito A; Kakudo K
Pathol Int; 2011 Oct; 61(10):577-81. PubMed ID: 21951666
[TBL] [Abstract][Full Text] [Related]
23. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19.
Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N
Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of human tumor-associated antigen, RCAS1, is significantly linked to dedifferentiation of thyroid carcinoma.
Ito Y; Yoshida H; Nakano K; Kobayashi K; Yokozawa T; Hirai K; Matsuzuka F; Matsuura N; Kuma K; Miyauchi A
Oncology; 2003; 64(1):83-9. PubMed ID: 12457035
[TBL] [Abstract][Full Text] [Related]
25. The diagnostic utility of cytokeratin 19 in differentiating malignant from benign thyroid lesions.
Wa Kammal WS; Yahaya A; Shah SA; Abdullah Suhaimi SN; Mahasin M; Mustangin M; Md Isa N
Malays J Pathol; 2019 Dec; 41(3):293-301. PubMed ID: 31901914
[TBL] [Abstract][Full Text] [Related]
26. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
[TBL] [Abstract][Full Text] [Related]
27. Can CD10 be used as a diagnostic marker in thyroid pathology?
Yegen G; Demir MA; Ertan Y; Nalbant OA; Tunçyürek M
Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
[TBL] [Abstract][Full Text] [Related]
28. Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules.
Viacava P; Bocci G; Tonacchera M; Fanelli G; DeServi M; Agretti P; Berti E; Goletti O; Aretini P; Resta ML; Bevilacqua G; Naccarato AG
Thyroid; 2007 Mar; 17(3):191-7. PubMed ID: 17381350
[TBL] [Abstract][Full Text] [Related]
29. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue.
Serini G; Trusolino L; Saggiorato E; Cremona O; De Rossi M; Angeli A; Orlandi F; Marchisio PC
J Natl Cancer Inst; 1996 Apr; 88(7):442-9. PubMed ID: 8618236
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study.
Kim SJ; Park JW; Yoon JS; Mok JO; Kim YJ; Park HK; Kim CH; Byun DW; Lee YJ; Jin SY; Suh KI; Yoo MH
J Korean Med Sci; 2004 Oct; 19(5):710-5. PubMed ID: 15483349
[TBL] [Abstract][Full Text] [Related]
31. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
32. Images in endocrine pathology: spindle cell lesion of the thyroid gland.
Rossi ED; Martini M; Cingolani N; Ranaldi R; Fadda G
Endocr Pathol; 2012 Jun; 23(2):132-4. PubMed ID: 22311188
[No Abstract] [Full Text] [Related]
33. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
34. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
Akslen LA; Varhaug JE
Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
[TBL] [Abstract][Full Text] [Related]
35. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
Tang J; Gui C; Qiu S; Wang M
World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
[TBL] [Abstract][Full Text] [Related]
36. [Differentiated microcarcinoma of the thyroid gland].
Sorrentino F; Atzeni J; Romano G; Buscemi G; Romano M
G Chir; 2010; 31(6-7):277-8. PubMed ID: 20646369
[TBL] [Abstract][Full Text] [Related]
37. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
38. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
39. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
40. Thyroid Hürthle cell tumors: research of potential markers of malignancy.
Donatini G; Beaulieu A; Castagnet M; Kraimps JL; Levillain P; Fromont G
J Endocrinol Invest; 2016 Feb; 39(2):153-8. PubMed ID: 26188382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
